SARS-CoV-2-specific immune responses after COVID-19 vaccination in solid organ transplant recipients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210523002

Enrollment

250

Registered

2021-05-23

Start date

2021-08-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Humoral immunity, cell-mediated immunity, COVID-19, immunocompromised

Interventions

SARS-CoV-2 vaccine

Experimental Biological/Vaccine

Vaccine arm

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All adult kidney, liver, heart transplant recipients

Exclusion criteria

Exclusion criteria: Active infection or allograft dysfunction Previous COVID-19 vaccination Allergic to COVID-19 vaccine Previous COVID-19 infection

Design outcomes

Primary

Measure	Time frame
Immunogenicity 4 weeks after the second shut of the vaccine SARS-CoV-2 neutralizing antibody	—

Secondary

Measure	Time frame
Safety 1 month Monitoring	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital

jackrapong.brm@mahidol.ac.th022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026